Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=desc&cHash=f5f2e5fdbfbf799a701ac9c5e77ce04b

Kurszettel

Alle Kurse

TOP

  • RENEURON (UK)3.60 GBP13.6%
  • EPIGENOMICS (D)5.74 EUR10.4%
  • PROTHENA PLC (IE)36.95 USD9.5%

FLOP

  • CYTOS (CH)0.13 CHF-18.8%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • THERAMETRICS (CH)0.10 CHF-9.1%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.82 EUR39.0%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.13 CHF-95.2%
  • BIONOR PHARMA (N)2.18 NOK-45.5%
  • DIAGENIC (N)0.78 NOK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6275.0%
  • IXICO (UK)67.00 GBP740.7%
  • PLETHORA (UK)10.62 GBP658.6%

FLOP

  • CYTOS (CH)0.13 CHF-96.8%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.95 CHF-71.1%

No liability assumed, Date: 24.04.2014